Literature DB >> 25808872

Tenascin-C Protects Cancer Stem-like Cells from Immune Surveillance by Arresting T-cell Activation.

Elena Jachetti1, Sara Caputo2, Stefania Mazzoleni3, Chiara Svetlana Brambillasca1, Sara Martina Parigi1, Matteo Grioni1, Ignazio Stefano Piras4, Umberto Restuccia5, Arianna Calcinotto6, Massimo Freschi7, Angela Bachi5, Rossella Galli3, Matteo Bellone8.   

Abstract

Precociously disseminated cancer cells may seed quiescent sites of future metastasis if they can protect themselves from immune surveillance. However, there is little knowledge about how such sites might be achieved. Here, we present evidence that prostate cancer stem-like cells (CSC) can be found in histopathologically negative prostate draining lymph nodes (PDLN) in mice harboring oncogene-driven prostate intraepithelial neoplasia (mPIN). PDLN-derived CSCs were phenotypically and functionally identical to CSC obtained from mPIN lesions, but distinct from CSCs obtained from frank prostate tumors. CSC derived from either PDLN or mPIN used the extracellular matrix protein Tenascin-C (TNC) to inhibit T-cell receptor-dependent T-cell activation, proliferation, and cytokine production. Mechanistically, TNC interacted with α5β1 integrin on the cell surface of T cells, inhibiting reorganization of the actin-based cytoskeleton therein required for proper T-cell activation. CSC from both PDLN and mPIN lesions also expressed CXCR4 and migrated in response to its ligand CXCL12, which was overexpressed in PDLN upon mPIN development. CXCR4 was critical for the development of PDLN-derived CSC, as in vivo administration of CXCR4 inhibitors prevented establishment in PDLN of an immunosuppressive microenvironment. Taken together, our work establishes a pivotal role for TNC in tuning the local immune response to establish equilibrium between disseminated nodal CSC and the immune system. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25808872     DOI: 10.1158/0008-5472.CAN-14-2346

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Tenascin-C and Integrin α9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment.

Authors:  Rebeca San Martin; Ravi Pathak; Antrix Jain; Sung Yun Jung; Susan G Hilsenbeck; María C Piña-Barba; Andrew G Sikora; Kenneth J Pienta; David R Rowley
Journal:  Cancer Res       Date:  2017-09-15       Impact factor: 12.701

2.  Osteopontin and the immune system: another brick in the wall.

Authors:  Sara Caputo; Matteo Bellone
Journal:  Cell Mol Immunol       Date:  2017-10-02       Impact factor: 11.530

3.  Brain tumor-initiating cells export tenascin-C associated with exosomes to suppress T cell activity.

Authors:  Reza Mirzaei; Susobhan Sarkar; Lauren Dzikowski; Khalil S Rawji; Lubaba Khan; Andreas Faissner; Pinaki Bose; V Wee Yong
Journal:  Oncoimmunology       Date:  2018-08-06       Impact factor: 8.110

Review 4.  Fibroblasts, an inconspicuous but essential player in colon cancer development and progression.

Authors:  Naofumi Mukaida; Soichiro Sasaki
Journal:  World J Gastroenterol       Date:  2016-06-21       Impact factor: 5.742

Review 5.  Internal Affairs: Tenascin-C as a Clinically Relevant, Endogenous Driver of Innate Immunity.

Authors:  Anna M Marzeda; Kim S Midwood
Journal:  J Histochem Cytochem       Date:  2018-01-31       Impact factor: 2.479

6.  Glioma Stem Cells but Not Bulk Glioma Cells Upregulate IL-6 Secretion in Microglia/Brain Macrophages via Toll-like Receptor 4 Signaling.

Authors:  Omar Dzaye; Feng Hu; Katja Derkow; Verena Haage; Philipp Euskirchen; Christoph Harms; Seija Lehnardt; Michael Synowitz; Susanne A Wolf; Helmut Kettenmann
Journal:  J Neuropathol Exp Neurol       Date:  2016-03-30       Impact factor: 3.685

7.  MicroRNA signature in the chemoprevention of functionally-enriched stem and progenitor pools (FESPP) by Active Hexose Correlated Compound (AHCC).

Authors:  Émilie A Graham; Jean-François Mallet; Majed Jambi; Hiroshi Nishioka; Kohei Homma; Chantal Matar
Journal:  Cancer Biol Ther       Date:  2017-09-08       Impact factor: 4.742

8.  Epidermal ROCK2 induces AKT1/GSK3β/β-catenin, NFκB and dermal tenascin C; but enhanced differentiation and p53/p21 inhibit papilloma.

Authors:  Siti F Masre; Nicola Rath; Michael F Olson; David A Greenhalgh
Journal:  Carcinogenesis       Date:  2020-10-15       Impact factor: 4.944

Review 9.  Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis.

Authors:  Sukanya Basu; Yang Dong; Rahul Kumar; Collene Jeter; Dean G Tang
Journal:  Semin Cancer Biol       Date:  2021-05-09       Impact factor: 15.707

Review 10.  Cancer stem cell-immune cell crosstalk in tumour progression.

Authors:  Defne Bayik; Justin D Lathia
Journal:  Nat Rev Cancer       Date:  2021-06-08       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.